Full Length Research Paper

Isolation and molecular characteristics of extended spectrum beta-lactamase-producing uropathogenic *Escherichia coli* isolated from hospital attendees in Ebonyi State, Abakaliki

Ugbo E. N.¹, Anyamene C. O.², Moses I. B.¹*, Ariom T. O.³, Agumah N. B.¹, Chukwunwejim C. R.⁴, Egbule C. U.⁵, Emioye A. A.⁶, Okata-Nwali O. D.⁶, Aneke C. J.⁷, Ugadu I. O.⁸ and Osu B. O.¹

¹Department of Applied Microbiology, Faculty of Sciences, Ebonyi State University, P. M. B. 053, Abakaliki, Ebonyi State, Nigeria.
²Department of Applied Microbiology and Brewing, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.
³Institute of Food Security, Environmental Resources and Agricultural Research, Federal University of Agriculture, Abeokuta, Ogun State, Nigeria.
⁴Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, Nigeria.
⁵Department of Science Laboratory Technology, Akanu-Ibiam Federal Polytechnic, Unwana, P.M.B. 1007, Ebonyi State, Nigeria.
⁶Department of Biology/Microbiology/Biotechnology, Federal University Ndufu-Alike, Ikwo Ebonyi State, Nigeria.
⁷Department of Applied Biochemistry, Faculty of Natural and Natural Sciences, Enugu State University of Science and Technology, Agbani, Nigeria.
⁸National Veterinary Research Institute, P. M. B. 01, Vom, Plateau State, Nigeria.

Received 24 September, 2020; Accepted 25 November, 2020

This present study was designed to determine the occurrence frequency of blaCTX-M and blaTEM genes in extended-spectrum beta-lactamase (ESBL)-producing uropathogenic *Escherichia coli*, and their antibiotic resistance patterns among hospital attendees in Abakaliki, Nigeria. Out of the 73 uropathogenic *E. coli* isolates analyzed, 52 were identified to be ESBL producers using double disk synergy technique. The frequency of beta-lactamase (bla) genes (CTX-M and TEM) among *E. coli* was molecularly determined by polymerase chain reaction (PCR). Out of 52 (71.2%) ESBL-producing uropathogenic *E. coli*, 17 (32.7%) were positive for blaTEM, 35 (67.3%) were positive for blaCTX-M while 8 (15.3%) harboured both blaTEM and blaCTX-M genes. CTX-M gene was the most prevalent gene. Isolates evaluated in our study were resistant to cefotaxime (83.6%), ceftazidime (79.5%), amoxycillin (72.6%), cefpodoxime (68.5%), aztreonam (61.6%), ceftriaxone (57.5%), and cefepime (37%). This study demonstrated the occurrence frequency of CTX-M and TEM genes in uropathogenic *E. coli* strains in Abakaliki. Even though molecular techniques are more reliable in the detection of ESBL production, routine clinical screening for ESBL-producing uropathogens using phenotypic method should be introduced and encouraged in clinical settings as they are less expensive. This will go a long way in checkmating drug resistance.

**Key words:** *Escherichia coli*, uropathogens, extended-spectrum beta-lactamase (ESBL), resistance genes, antibiotics.
INTRODUCTION

Microbial resistance by pathogenic *Escherichia coli* is a major worldwide concern. Antibacterial agents, especially beta-lactams are becoming less useful against *Enterobacteriaceae* (Dia et al., 2015). Urinary tract infections (UTIs), a common nosocomial and community-acquired bacterial infection, occur in all genders and age groups (Abdulaziz et al., 2018). Antibiotic resistance by *E. coli* to numerous antibiotics is now developing and evolving (Raju et al., 2019). *E. coli* implicated in UTIs are becoming multidrug-resistant as a result of their extended-spectrum beta-lactamase (ESBL)-producing ability. Beta-lactam resistance is mediated by ESBL genes that are mostly encoded by plasmid (Topaloglu et al., 2010). ESBLs are a branch of beta-lactamases that have the ability of hydrolyzing the β-lactam ring of penicillins, aztreonam, and cephalosporins. However, they often remain susceptible to cephapymcs and carbapenems (imipenem and ertapenems) (Shehani and Sui, 2013). *E. coli* could acquire some resistance factors from environmental bacteria of surroundings; this could transmit its resistance genes to other bacterial pathogens in arrays of habitats. Diagnosing of UTIs accurately and proper usage of antimicrobials for treatment and prevention are paramount in reducing drug resistance (Roshan et al., 2020). CTX-M, TEM, SHV, and AmpC beta-lactamase genes have been identified in *E. coli* isolates from UTI patients over the years (Koshesh et al., 2017). TEM (Temoneira), SHV (sulfhydryl variable), and CTX-M (ceftoximase) belong to class A ESBLs. Shahid et al. (2011) and Iroha et al. (2010) observed different frequencies of ESBLs among Gram-negative bacteria to range between 6 and 88% in different health institution settings. Sima et al. (2016) also reported CTX-M (74%), SHV (45%), and TEM (67%) genes in *E. coli* isolates. CTX-M have been increasingly recorded in various clinical specimens and *E. coli* remains the major organism implicated (Mohammed et al., 2011). This study was therefore designed to molecularly characterize ESBL-producing uropathogenic *Escherichia coli* from hospital attendees in Ebonyi State, Nigeria.

METHODOLOGY

Collection of samples

Seventy three (73) *E. coli* were obtained from mid-stream urine samples of 133 patients attending Federal Teaching Hospital, Abakaliki metropolis, Nigeria between February, 2018 and November, 2018. Sterile universal container was used to collect urine samples from patients suspected of UTIs. Every patient was properly instructed on self-collection of urine samples. The samples were immediately transported to the laboratory of Applied Microbiology Department, Faculty of Sciences, Ebonyi State University, Abakaliki for bacteriological analysis.

Culturing of samples, isolation, and biochemical characterization of bacterial isolates

Mid-stream urine samples were streaked on MacConkey agar aseptically and then incubated for 24 h at exactly 37°C. Plates were then observed for *E. coli* growth (red or pink colonies) on MacConkey agar. These suspected bacterial isolates were thereafter characterized by standard microbiology techniques such as motility test, Gram-stain, and other biochemical tests such as methyl red, indole, urease test, Voges-Proskauer, and citrate (Cheesbrough, 2010; Moses et al., 2018). Pure colonies of isolates were then inoculated on nutrient agar slants, incubated for 24 h at 37°C and kept in a refrigerator for future use at 4°C (Moses et al., 2018).

Ethical clearance

Ethical approval was given by the Federal Teaching Hospital, Abakaliki (FETHA) research and ethical committee

Antimicrobial susceptibility test

Isolates were tested to evaluate their antimicrobial sensitivity patterns by the Kirby-Bauer disk diffusion method. Test organisms were adjusted to McFarland equivalent standards and inoculated using sterile swab stick on Mueller-Hinton (MH) agar plates. Cefpodoxime (10 µg), amoxicillin (20 µg), ceftriaxone (30 µg), ceftazidime (30 µg), cefepime (30 µg), cefotaxime (30 µg), and aztreonam (30 µg) antibiotic discs were carefully placed on the MH agar using sterile forceps. Antibiotics were allowed to properly diffuse for 10 min and plates were then incubated for 18 h at 37°C. The inhibition zone diameters (IZDs) were measured and results were interpreted as resistant or susceptible as per the CLSI guidelines after incubation (CLSI, 2018; Moses et al., 2020). The confirmed uropathogenic *E. coli* were stored in agar slant at -70°C and were subjected to further ESBL phenotypic and molecular identification.

Phenotypic test for ESBL detection

The turbidity of suspected potential ESBL-producers were properly adjusted to 0.5 McFarland standards. Sterile swab sticks were then used to make lawn culture of the standardized isolates on the surface of MH agar plates (CLSI, 2018). Cefotaxime and ceftazidime antibiotic discs were placed at a distance of 15 mm centre-to-centre from the central disc containing amoxicillin/clavulanic acid (20 µg/10 µg). Plate was incubated overnight at 37°C. An increase of ≥5 mm in the IZD for either of the cephalosporins (ceftaxime and ceftazidime) tested in combination with amoxicillin/clavulanic acid versus its zone when tested alone confirms ESBL production (Sima et al., 2016). *E. coli* ATCC 25922 was used as quality control.

*Corresponding author. E-mail: ben_iyke70@yahoo.com. Tel: +2348134136233.*

Author(s) agree that this article remain permanently open access under the terms of the [Creative Commons Attribution License 4.0 International License](https://creativecommons.org/licenses/by/4.0/).
samples analyzed between February and November, 2018, 73 uropathogenic *E. coli* isolates were obtained and fifty 52 isolates were ESBL producers as investigated phenotypically using double disk diffusion techniques (Tables 2 and 3). The isolates that demonstrated resistance or reduced susceptibility to ceftazidime, cefotaxime, and cefpodoxime were subjected to ESBL phenotypic detection. The keyhole pattern exhibited by uropathogenic *E. coli* isolates expressing ESBL production is as shown in Plate 1. This property is an important characteristic of ESBL-producing bacteria as a result of the synergistic effect between amoxicillin-clavulanic acid (a beta-lactamase inhibitor) and third generation cephalosporins (ceftazidime and cefotaxime). Three different sets of primers were used to amplify 16S rRNA, blaCTX-M, and blaTEM genes (Table 1). Agarose gel showed PCR product of the amplified 16S rRNA gene among the isolates to be 797 bp (Figure 1). Out of the 52 ESBL positive uropathogenic *E. coli* isolates, 17 (32.7%) harboured blaTEM gene, 35 (67.3%) harboured blaCTX-M gene, while 8 (15.3%) harboured both blaTEM and blaCTX-M genes (Table 4). PCR product band sizes of blaCTX-M and blaTEM genes were estimated to be 861 and 585 bp, respectively (Figure 2). Uropathogenic *E. coli* evaluated in this study exhibited varying frequencies of resistance to antibiotics tested. Isolates exhibited resistance to cefotaxime (83.6%), ceftazidime (79.5%), amoxycillin (72.6%), cefpodoxime (68.5%), aztreonam (61.6%), ceftriaxone (57.5%), and cefepime (37%) (Table 2). Indiscriminate use and abuse of beta-lactam antibiotics by individuals have caused problems in the treatment of microbial infections and diseases caused by these antibiotic-resistant organisms as a result of ESBL production. Some ESBL-producing bacteria failed to be detected using disk diffusion technique, thus resulting in serious treatment failures among infected patients/individuals (Umadevi et al., 2011). The lack of routine screening and detection of bacteria among clinical isolates in hospitals with the ability to produce ESBL was evident in this present study. These types of discrepancies between susceptibility data and disc diffusion call for improved ESBL detection and incorporation into routine susceptibility techniques in

### RESULTS AND DISCUSSION

This work provided insights into the antibiotic resistance profiles and molecular characteristics of uropathogenic *E. coli* with the ability to produce ESBLs. Out of the 130 samples analyzed between February and November, 2018, 73 uropathogenic *E. coli* isolates were obtained and fifty 52 isolates were ESBL producers as investigated phenotypically using double disk diffusion techniques (Tables 2 and 3). The isolates that demonstrated resistance or reduced susceptibility to ceftazidime, cefotaxime, and cefpodoxime were subjected to ESBL phenotypic detection. The keyhole pattern exhibited by uropathogenic *E. coli* isolates expressing ESBL production is as shown in Plate 1. This property is an important characteristic of ESBL-producing bacteria as a result of the synergistic effect between amoxicillin-clavulanic acid (a beta-lactamase inhibitor) and third generation cephalosporins (ceftazidime and cefotaxime). Three different sets of primers were used to amplify 16S rRNA, blaCTX-M, and blaTEM genes (Table 1). Agarose gel showed PCR product of the amplified 16S rRNA gene among the isolates to be 797 bp (Figure 1). Out of the 52 ESBL positive uropathogenic *E. coli* isolates, 17 (32.7%) harboured blaTEM gene, 35 (67.3%) harboured blaCTX-M gene, while 8 (15.3%) harboured both blaTEM and blaCTX-M genes (Table 4). PCR product band sizes of blaCTX-M and blaTEM genes were estimated to be 861 and 585 bp, respectively (Figure 2). Uropathogenic *E. coli* evaluated in this study exhibited varying frequencies of resistance to antibiotics tested. Isolates exhibited resistance to cefotaxime (83.6%), ceftazidime (79.5%), amoxycillin (72.6%), cefpodoxime (68.5%), aztreonam (61.6%), ceftriaxone (57.5%), and cefepime (37%) (Table 2). Indiscriminate use and abuse of beta-lactam antibiotics by individuals have caused problems in the treatment of microbial infections and diseases caused by these antibiotic-resistant organisms as a result of ESBL production. Some ESBL-producing bacteria failed to be detected using disk diffusion technique, thus resulting in serious treatment failures among infected patients/individuals (Umadevi et al., 2011). The lack of routine screening and detection of bacteria among clinical isolates in hospitals with the ability to produce ESBL was evident in this present study. These types of discrepancies between susceptibility data and disc diffusion call for improved ESBL detection and incorporation into routine susceptibility techniques in

### DNA extraction and polymerase chain reaction (PCR) detection of blaCTX-M and blaTEM genes

Genomic DNA was extracted from pure colonies of an overnight growth of *E. coli* on Luria-Bertani agar using QIAamp DNA isolation columns (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The purity and concentration of extracted DNA was determined using NanoDrop-Spectrophotometer at an absorbance of A260/280. Quality control of extracted DNA was done by testing all extracted genomic DNA for 16S rRNA gene. Table 1 shows the oligonucleotide primer sequences and the targeted genes (blaCTX-M and blaTEM) sizes. The PCR reactions for detection of blaCTX-M and blaTEM genes were done in a total reaction volume of 25 μl which contains 12.5 μl of Master Mix Red, 0 μl of Sigma water, 0.25 μl of forward primer, 0.25 μl reverse primer, and 2 μl of the isolated genomic DNA. PCR was done with a C1000 Touch Thermo Cycler (Bio-Red) (Azam et al., 2016; Gudjónsdóttir, 2015).

### Gel Electrophoresis

Exactly 1.0 g of agarose and 100 ml of 1X Tris-acetate-ethylenediaminetetraacetate (TAE; pH 8.0) buffer (Bio-Rad) was used to prepare 1% (w/v) agarose gel. The mixture was then heated up for about 3 min in a microwave for total dissolution of agarose. It was then cooled to about 50°C and ethidium bromide (1 μl/ml) was added to stain the prepared agarose gel. The molten agarose gel was then cast into a gel casting tray containing combs and allowed to solidify. After about 30 min of agarose gel solidification, gel combs were carefully removed and gel casting tray containing the resistance was placed into a gel electrophoresis chamber filled with TAE buffer (40 mM Tris, 20 mM acetic acid, and 100 mM EDTA pH 8.0). For each run, 5 μl of Extend Quick-Load DNA Ladder (1 kb; New England, Bio Labs) was added to one of the wells to estimate the band sizes and 5 μl of negative control, comprising Sigma water, was added to another well. Exactly 5 μl of each PCR product was carefully and properly loaded in the remaining wells. Electrophoresis was run at 80 V and 400 mA (mini Ampere) for exactly 1 h. Gels were then visualized and photographed by a gel documentation system (Bio-Rad) (Gudjónsdóttir, 2015).

### Table 1. PCR primers of 16S rRNA and ESBL gene.

| Primer name | Targeted gene | Primer sequence (5'-3') | Amplicon product size (bp) |
|-------------|---------------|-------------------------|----------------------------|
| 27          | 16S rRNA      | F-AGT TTG ATC MTG GCT CAG R-GGA CTA CHA GGG TAT CTA AT | 797, Gudjónsdóttir (2015) |
| 805         |               | F-ATGAGTATTCACATTTCCGTGT R-TTAACATGCCTTAATCGTGAGG | 861, Azam et al. (2016) |
| TEM         | blaTEM        | F-SCS ATG TGC AGY ACC AGT AA R-ACC AGA AYG AGC GGB GC | 585, Gudjónsdóttir (2015) |
| CTX-M       | blaCTX-M      |                           |                           |
Table 2. Susceptibility patterns of uropathogenic *E. coli*.

| Antibiotics (concentrations in µg) | *Escherichia coli*, No. (%) |   |   |
|-----------------------------------|-----------------------------|---|---|
|                                   | *             | S | R |
| Cefepime (30)                     | 46 (63.0)      |   | 27 (37.0) |
| Ceftazidime (30)                  | 15 (20.5)      |   | 58 (79.5) |
| Ceftriaxone (30)                  | 31 (42.5)      |   | 42 (57.5) |
| Cefpodoxime (10)                  | 23 (31.5)      |   | 50 (68.5) |
| Aztreonam (30)                    | 28 (38.4)      |   | 45 (61.6) |
| Cefotaxime (30)                   | 12 (16.4)      |   | 61 (83.6) |
| Amoxycillin (20)                  | 20 (27.4)      |   | 53 (72.6) |

S-Susceptible; R-Resistant.

Table 3. Prevalence of ESBL-producing uropathogenic *Escherichia coli*.

| Sample source | Sample size | Uropathogenic *E. coli*, No. (%) | ESBL-producing *E. coli*, No. (%) |
|---------------|-------------|---------------------------------|----------------------------------|
| Urine         | 130         | 73 (56.2)                       | 52 (71.2)                        |

Plate 1. Picture of Double Disc Synergy test for ESBL-producing Uropathogenic *Escherichia coli*.

hospitals. In the study done by other researchers, it was found that *E. coli* is usually implicated in urinary tract infections (UTIs) and frequently identified as ESBL-producers (Abhilash et al., 2010; Shanthi and Sekar, 2010; Umadevi et al., 2011). Phenotypic screening tests for ESBL detection only confirm whether ESBL is
produced by the isolate but does not detect the presence of ESBL subtype. Currently, many researchers in the world have stated that although molecular methods appear more sensitive, but require specialized equipment and expertise, time consuming, and expensive (Sima et al., 2016; Varun and Parijath, 2014). A definitive identification is achievable only through molecular techniques. However, molecular methods such as PCR are not readily available in the hospital setting and can only be seen in research facilities. A study by Dia et al. (2015) identified 32 E. coli isolates to be ESBL producers and blaCTX-M gene was reported to be the most frequent ESBL gene with 90.63% frequency. Similarly, Ugbo et al. (2020) and Sharma et al. (2010)}
reported 55 and 56% blaTEM frequency, respectively among E. coli of clinical origin; and this is in agreement with this present study where we reported 32.7 and 67.3% frequencies for TEM and CTX-M genes, respectively. Roshan et al. (2020) reported 40.3% multidrug-resistant ESBL-producing isolates of E. coli; of which blaTEM (83.8%) and blaCTX (66.1%) were the common ESBL genotypes detected. In a study by Abdulaziz et al. (2018), blaCTX-M gene (93.9%) was the most prevalent ESBL genotype. Multiple ESBL gene carriage was also identified to be 45.5% among the uropathogenic E. coli (Abdulaziz et al., 2018). These observations by Roshan et al. (2020) and Abdulaziz et al. (2018) are in agreement with our present study, where blaCTX-M genotype was the most prevalent. A study done by Zongo et al. (2015) in Burkina Faso showed that high frequency (75.5%) of ESBL-producers was observed among E. coli isolates. They also reported that among the isolates with ESBL-producing ability, CTX-M (65, 49%) was the most prevalent, followed by TEM (25, 73%), and SHV (18, 71%).

Conclusion

This study has shown the presence of uropathogenic E. coli with ESBL-producing ability in the urine samples of hospital attendees in Abakaliki, Nigeria. Our study has also demonstrated the presence of ESBL genes, CTX-M and TEM, in the identified ESBL-producing uropathogenic E. coli isolates. Interestingly, blaCTX-M gene was the most predominant ESBL gene among the isolates in our study area. This research work showed that genotypic methods via PCR technique is more reliable for ESBL detection among bacterial isolates as PCR technique detected the presence of blaCTX-M and blaTEM in uropathogenic E. coli isolates. Thus, routine clinical detection of ESBL using phenotypic method should be introduced in the clinical setting since molecular methods are expensive to checkmate drug resistance due to ESBL production by bacteria. It is imperative that future studies should incorporate sequencing of isolates and resistance genes amplicons, together with bioinformatics so as to decipher the clonal relatedness/diversity and epidemiological identities of bacterial pathogens. This will greatly help in tracking disease occurrence, origins and sources of bacterial pathogens, and curtailing the spread of multidrug-resistant bacterial pathogens.

CONFLICT OF INTERESTS

The authors have not declared any conflict of interests.

REFERENCES

Abdulaziz A, Ahmad AJ, Abdullah AA (2018). Prevalence of Multidrug Resistance and Extended-Spectrum β-Lactamase Carriage of Clinical Uropathogenic Escherichia coli Isolates in Riyadh, Saudi Arabia. International Journal of Microbiology Article ID 302885.

Abdulaziz KP, Veeraraghavan B, Abraham OC (2010). Epidemiology and Outcome of Bacteremia Caused by Extended Spectrum Beta-Lactamase (ESBL)-producing Escherichia Coli and Klebsiella Spp. in a Tertiary Care Teaching Hospital in South India. Journal of Association of Physicians India 58:13-17.

Azam M, Arif TJ, Qazi MR (2016). BlaCTX-M-152, a novel variant of CTX-M-group-25, identified in a study performed on the prevalence of multidrug resistance among natural inhabitants of river Yamuna, India. Frontiers in Microbiology 7(176):1-13.

Cheesbrough M (2010). District Laboratory Practice in Tropical Countries, Part two, 2nd edn. Cambridge University Press, UK. Pp. 143-180.

Clinical and Laboratory Standards Institute (CLSI) (2018). Performance standards for antimicrobial susceptibility testing; M02 13th edition Volume 38 Number 1, Clinical and Laboratory Standards Institute, Wayne, PA.

Dia ML, Ngom B, Diagne R, Ka R, Lo S, Cisse MF, Sow AI. (2015). Molecular detection of CTX-M-15-type β-lactamases in Escherichia coli strains from Senegal. New Microbe and New Infectious 9:45-46.

Gudjonsdottir HB (2015). ESBL-producing Escherichia coli: a molecular study on bacterial relatedness and resistance genes in isolates from the period 2006-2014. Thesis for the degree of Master of Science University of Iceland. Faculty of Medicine, Department of Biomedical Sciences, School of Health Sciences, P. 29.

Iroha IR, Amadi ES, Oji AE, Nwuzo AC, Ejikegwu PC (2010). Detection of plasmid borne extended – spectrum beta – lactamase enzymes from blood and urine isolates of Gram – negative bacteria from a university teaching hospital in Nigeria. Current Research in Bacteriology 3(2):77-83.

Koshesh M, Mansouri S, Hashemizadeh Z, Kalantar-Neyestanaki D (2017). Identification of extended-spectrum beta-lactamase genes and AmpC beta-lactamase in clinical isolates of Escherichia coli recovered from patients with urinary tract infections in Kerman, Iran. Archives of Pediatric Infectious Diseases 5(2):1-6.

Mohammed S, Abida M, Rakesh B (2011). Increasing secondary bacterial infections with Enterobacteriaceae harboring blaCTX-M-15 and blaCMY-6 in patients with bronchogenic carcinoma: an emerging point of concern. Asian Pacific Journal of Tropical Medicine 5:12.

Moses IB, Esimone CO, Iroha IR, Ugbo EN, Orji JO, Nwuzo AC, Nwakaeze EA, Agumah NB, Emioye AA, Ukpai EG, Ogene LN (2020). First report on the antibiotic resistance profiles and virulence genes of Staphylococcus pseudintermedius colonizing dogs and humans in Abakaliki, South-East Nigeria. Research Journal of Medical Microbiology 15:22-33.

Moses IB, Ugbo EN, Odah EE, Iroha IR, Agumah MB, Ukpai EG, Elu UC, Uzoeto HO, Okamika CT, Okata-Nwali D (2018). Antibiogram and Phenotypic Characterization of E. coli Isolated from Nigeria’s Paper Currencies obtained from Butchers in Ebonyi State. Archives of Clinical Microbiology 9(4):1-5.

Raju S, Santosh K, Pramod P, Karan K, Sajani G, Anita B, Sunil L, Narayan DP, Manisha, S, Bishnu PM (2019). Extended spectrum β-lactamase producing uropathogenic Escherichia coli and the correlation of biofilm with antibiotics resistance in Nepal. Annals of Clinical Microbiology and Antimicrobials 18(42):1-6.

Roshan P, Balkrishna A, Sumesh SS, Govardhan J, Basista PR, Narayan PP (2020). Genotypes among Multidrug-Resistant Uropathogenic Escherichia coli Clinical Isolates from a Teaching Hospital of Nepal. Interdisciplinary Perspectives on Infectious Diseases Article ID 6525826.

Shahi M, Singh A, Sobia F, Rashid M, Malik A, Shukla I (2011). BlaCTX-M, blaTEM, and blaSHV in Enterobacteriaceae from North-Indian tertiary hospital: high occurrence of combination genes. Asian Pacific Journal of Tropic Medicine 4(2):101-105.

Shanthi M, Sekar U (2010). Extended Spectrum Beta Lactamase Producing Escherichia Coli and Klebsiella Pneumoniae: Risk Factors for Infection and Impact of Resistance on Outcomes. Journal of Association of Physicians India 58:41-44.

Sharma J, Sharma M, Ray P (2010). Detection of TEM & SHV genes in
Escherichia coli and Klebsiella pneumoniae isolates in a tertiary care hospital from India. Indian Journal of Medical Research 132:332-336.

Shehani T, Sui ML (2013). Isolation of Extended spectrum beta-lactamase (ESBL) producing bacteria from urban surface water in Malysia. Malaysia Journal of Medical Science 20(3):14-22.

Sima SS, Mehdi G, Fattaneh S (2016). Relation between blaTEM, blaSHV and blaCTX-M genes and acute urinary tract infections. Journal of Acute Disease 5(1):71-76.

Topaloglu R, Er I, Dogan BG, Bilginer Y, Ozaltin F, Besbas N (2010). Risk factors in community-acquired urinary tract infections caused by ESBL-producing bacteria in children. Pediatric Nephrology 25(5):919-925.

Ugbo EN, Anyamene CO, Moses IB, Iroha IR, Babalola OO, Ukpai EG, Chukwunweim CR, Egbulu CU, Emiaye AA, Okata-Nwali OD, Igwe OF, Ugadu IO (2020). Prevalence of blaTEM, blaSHV, and blaCTX-M genes among extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae of clinical origin. Gene Reports 21:100909.

Umadevi S, Kandhakumari G, Joseph NM, Kumar S, Easow JM, Stephen S, Singh UK (2011). Prevalence and antimicrobial Susceptibility pattern of ESBL producing Gram Negative Bacilli. Journal of Clinical and Diagnostic Research 5(2):236-239.

Varun G, Parjath NG (2014). Detection of TEM and SHV genes in extended spectrum beta lactamase (ESBL) producing Escherichia coli & Klebsiella pneumoniae isolated from a tertiary care cancer hospital. National Journal of Medical Research 4(3):201-204.

Zongo KJ, Metuor AD, Compaore LG, Sanou I, Sangare L, Simpore J, Zeba B (2015). First detection of bla TEM, SHV and CTX-M among Gram negative bacilli exhibiting extended spectrum β-lactamase phenotype isolated at University Hospital Center, Yalgado Ouedraogo, Ouagadougou, Burkina Faso. African Journal of Biotechnology 14(14):1174-1180.